Ganciclovir pharmacokinetics during renal impairment

K. D. Lake, C. V. Fletcher, K. R. Love, D. C. Brown, L. D. Joyce, M. R. Pritzker

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.

Original languageEnglish (US)
Pages (from-to)1899-1900
Number of pages2
JournalAntimicrobial Agents and Chemotherapy
Volume32
Issue number12
DOIs
StatePublished - Jan 1 1988

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Lake, K. D., Fletcher, C. V., Love, K. R., Brown, D. C., Joyce, L. D., & Pritzker, M. R. (1988). Ganciclovir pharmacokinetics during renal impairment. Antimicrobial Agents and Chemotherapy, 32(12), 1899-1900. https://doi.org/10.1128/AAC.32.12.1899